KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Consolidated Net Income (2019 - 2025)

Historic Consolidated Net Income for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $444.2 million.

  • Royalty Pharma's Consolidated Net Income fell 4491.14% to $444.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 2400.27%. This contributed to the annual value of $1.3 billion for FY2024, which is 2172.09% down from last year.
  • As of Q3 2025, Royalty Pharma's Consolidated Net Income stood at $444.2 million, which was down 4491.14% from $90.6 million recorded in Q2 2025.
  • Royalty Pharma's 5-year Consolidated Net Income high stood at $806.8 million for Q2 2021, and its period low was -$610.0 million during Q4 2022.
  • Moreover, its 5-year median value for Consolidated Net Income was $221.8 million (2021), whereas its average is $287.9 million.
  • Per our database at Business Quant, Royalty Pharma's Consolidated Net Income crashed by 123661.01% in 2022 and then skyrocketed by 1024352.91% in 2025.
  • Over the past 5 years, Royalty Pharma's Consolidated Net Income (Quarter) stood at $53.7 million in 2021, then tumbled by 1236.61% to -$610.0 million in 2022, then surged by 217.63% to $717.6 million in 2023, then plummeted by 53.41% to $334.4 million in 2024, then surged by 32.86% to $444.2 million in 2025.
  • Its last three reported values are $444.2 million in Q3 2025, $90.6 million for Q2 2025, and $433.4 million during Q1 2025.